NCT03227861View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

PHASE3CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

July 31, 2017

Primary Completion Date

January 3, 2019

Study Completion Date

September 4, 2019

Conditions
HIV-1
Interventions
DRUG

DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC

Participants will receive oral tablet containing D 800 mg /C 150 mg /F 200 mg /TAF 10 mg FDC once daily within 24 hours of the screening/ baseline visit.

Trial Locations (16)

20009

Whitman Walker Health, Washington D.C.

31401

Chatham County Health Department, Savannah

32803

Orlando Immunology Center, Orlando

33136

University of Miami, Miami

34982

Midway Immunology and Research Center, Ft. Pierce

60612

The Ruth M. Rothstein CORE Center, Chicago

75246

North Texas Infectious Diseases Consultants, Dallas

76104

Texas Centers for Infectious Disease Associates, Fort Worth

77004

Therapeutic Concepts - Donald R Watkins Foundation, Houston

77098

Gordon Crofoot, MD, Houston

85012

Spectrum Medical Group, Phoenix

87109

Southwest CARE Center, Albuquerque

87505

Southwest CARE Center, Santa Fe

90028

Jeffrey Goodman Clinic - DBA Los Angeles Gay and Lesbian Center, Los Angeles

93301

The Office of Franco Felizarta, MD, Bakersfield

07102

Saint Michaels Medical Center - Infectious Disease, Newark

All Listed Sponsors
lead

Janssen Scientific Affairs, LLC

INDUSTRY

NCT03227861 - A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care | Biotech Hunter | Biotech Hunter